Cartesian Therapeutics pioneers mRNA cell therapies designed to treat autoimmune diseases by engineering autologous CAR-T cells. Its lead product, Descartes-08, is an mRNA-based therapy directed against BCMA currently in late-stage clinical development for generalized myasthenia gravis. The platform aims to bring the benefits of cell therapy to patients with immunological conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.3 | — | 13.3 | — |
| Q3 2025 | 0.5 | — | -35.9 | — |
| Q4 2025 | 0.9 | — | -92.6 | — |
| Q1 2026 | 0.1 | — | -39.2 | — |
| Q2 2026 | 0 | -100% | 13.7 | 3.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Lyell Immunopharma, Inc. (LYEL), TON Strategy Co (TONX), Invivyd, Inc. (IVVD), Neostellar Capital Corp. (NSLR), TROOPS, Inc. (TROO), Harvard Ave Acquisition Corporation (HAVA)